News Image

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

Provided By GlobeNewswire

Last update: May 13, 2025

Company had a strong start to 2025, emerging as an R&D-focused organization

Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025

Read more at globenewswire.com

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (7/29/2025, 8:00:01 PM)

After market: 1.08 +0.01 (+0.93%)

1.07

-0.02 (-1.83%)



Find more stocks in the Stock Screener

Follow ChartMill for more